{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:27:25Z","timestamp":1779395245155,"version":"3.53.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":858,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18059186"],"award-info":[{"award-number":["18059186"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18059186"],"award-info":[{"award-number":["18059186"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Among consecutive 4056 patients in the Kyoto Congestive Heart Failure registry, we analysed 3802 patients after excluding patients on dialysis, prior or unknown tolvaptan use at admission, and unknown timing of tolvaptan use, and we divided them into two groups: tolvaptan use (N = 773) and no tolvaptan use (N = 3029). The prevalence of tolvaptan use varied widely from 48.7% to 0% across the participating centres. Factors independently associated with tolvaptan use were diabetes, poor medical adherence, oedema, pleural effusion, hyponatraemia, estimated glomerular filtration rate &amp;lt; 30 mL\/min\/1.73 m2, moderate\/severe tricuspid regurgitation, dobutamine infusion within 24 h, and additional inotropes infusion beyond 24 h after admission. The mortality rate at 90 days after admission was significantly higher in the tolvaptan use group than in the no tolvaptan use group (14.3% vs. 8.6%, P = 0.049). However, after adjustment, the excess mortality risk of tolvaptan use relative to no tolvaptan use was no longer significant (hazard ratio = 1.53, 95% confidence interval = 0.77\u20133.02, P = 0.22). Patients with tolvaptan use had a longer hospital stay [median (interquartile range): 22 (15\u201334) days vs. 15 (11\u201321) days, P &amp;lt; 0.0001] and a higher prevalence of worsening renal failure (47.0% vs. 31.8%, P &amp;lt; 0.0001) and worsening heart failure (24.8% vs. 14.4%, P &amp;lt; 0.0001) than those without.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AHF patients with tolvaptan use had more congestive status with poorer in-hospital outcomes and higher short-term mortality than those without tolvaptan use.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02334891 (NCT02334891) and https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000017241 (UMIN000015238).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14494","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T02:40:56Z","timestamp":1693363256000},"page":"3141-3151","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry"],"prefix":"10.1093","volume":"10","author":[{"given":"Ryusuke","family":"Nishikawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology, Hyogo College of Medicine , Nishinomiya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yaku","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Inuzuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shiga General Hospital , Moriyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodo","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Tenri Hospital , Tenri ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neiko","family":"Ozasa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shizuoka General Hospital , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shizuoka General Hospital , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Seko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kitai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center , Amagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Red Cross Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kishiwada City Hospital , Kishiwada ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Komasa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Electric Power Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital , Kurashiki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morinaga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital , Kitakyushu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Toyofuku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Wakayama Medical Center , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital , Kitakyushu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital , Kurashiki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine , Matsumoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the KCHF Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"2026012113215195800_ehf214494-bib-0001","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0002","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/cir.0b013e31828124ad","article-title":"Heart disease and stroke statistics\u20142013 update: A report from the American Heart Association Writing Group Members HHS Public Access","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"2026012113215195800_ehf214494-bib-0003","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ahj.2007.03.012","article-title":"Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"153","author":"Fonarow","year":"2007","journal-title":"Am Heart J"},{"key":"2026012113215195800_ehf214494-bib-0004","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1253\/circj.72.489","article-title":"Impending epidemic\u2014Future projection of heart failure in Japan to the year 2055","volume":"72","author":"Okura","year":"2008","journal-title":"Circ J"},{"key":"2026012113215195800_ehf214494-bib-0005","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012113215195800_ehf214494-bib-0006","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"An oral vasopressin antagonist, in patients hospitalized for heart failure","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"2026012113215195800_ehf214494-bib-0007","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026012113215195800_ehf214494-bib-0008","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.614","article-title":"Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis","volume":"8","author":"Luo","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2026012113215195800_ehf214494-bib-0009","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0010","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00380-015-0780-z","article-title":"Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure","volume":"31","author":"Matsukawa","year":"2016","journal-title":"Heart Vessels"},{"key":"2026012113215195800_ehf214494-bib-0011","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00380-017-1039-7","article-title":"Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure","volume":"33","author":"Matsukawa","year":"2018","journal-title":"Heart Vessels"},{"key":"2026012113215195800_ehf214494-bib-0012","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2021.16.PO11","article-title":"Early initiation of tolvaptan is associated with early discharge in elderly heart failure patients","volume":"16","author":"Kiuchi","year":"2021","journal-title":"Eur Cardiol Rev"},{"key":"2026012113215195800_ehf214494-bib-0013","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98173-8","article-title":"Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan","volume":"11","author":"Yamazaki","year":"2021","journal-title":"Sci Rep"},{"key":"2026012113215195800_ehf214494-bib-0014","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ehf2.13111","article-title":"Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan","volume":"8","author":"Kuragaichi","year":"2021","journal-title":"ESC Heart Failure"},{"key":"2026012113215195800_ehf214494-bib-0015","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1253\/circj.CJ-17-1386","article-title":"Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan: Observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) registry","volume":"82","author":"Yaku","year":"2018","journal-title":"Circ J"},{"key":"2026012113215195800_ehf214494-bib-0016","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ehf2.12138","article-title":"Kyoto Congestive Heart Failure (KCHF) study: Rationale and design","volume":"4","author":"Yamamoto","year":"2017","journal-title":"ESC Heart Failure"},{"key":"2026012113215195800_ehf214494-bib-0017","volume-title":"Ethical Guidelines for Medical and Health Research Involving Human Subjects","author":"Ministry of Health, Labour and Welfare"},{"key":"2026012113215195800_ehf214494-bib-0018","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0019","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/ejhf.333","article-title":"In-hospital worsening heart failure","volume":"17","author":"Butler","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012113215195800_ehf214494-bib-0020","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/eht515","article-title":"Renal dysfunction and heart failure: Things are seldom what they seem","volume":"35","author":"Filippatos","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113215195800_ehf214494-bib-0021","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60404-9","article-title":"Association with controlling nutritional status (CONUT) score and in-hospital mortality and infection in acute heart failure","volume":"10","author":"Kato","year":"2020","journal-title":"Sci Rep"},{"key":"2026012113215195800_ehf214494-bib-0022","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2169\/internalmedicine.55.7133","article-title":"Dual impact of tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention","volume":"55","author":"Masuda","year":"2016","journal-title":"Intern Med"},{"key":"2026012113215195800_ehf214494-bib-0023","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.667522","article-title":"Association between sleep apnea and valvular heart diseases","volume":"8","author":"Pelaia","year":"2021","journal-title":"Front Med"},{"key":"2026012113215195800_ehf214494-bib-0024","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/eci.13887","article-title":"Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients","volume":"53","author":"Armentaro","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"2026012113215195800_ehf214494-bib-0025","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"2026012113215195800_ehf214494-bib-0026","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1053\/j.ajkd.2015.12.024","article-title":"Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: A randomized trial (INSIGHT)","volume":"67","author":"Verbalis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026012113215195800_ehf214494-bib-0027","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jjcc.2018.10.003","article-title":"Update of acute and long-term tolvaptan therapy","volume":"73","author":"Imamura","year":"2019","journal-title":"J Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0028","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0029","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012113215195800_ehf214494-bib-0030","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm8111854","article-title":"Loop diuretic administration in patients with acute heart failure and reduced systolic function: Effects of different intravenous diuretic doses and diuretic response measurements","volume":"8","author":"Ruocco","year":"2019","journal-title":"J Clin Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3141\/66227955\/eschf_10_5_3141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3141\/66227955\/eschf_10_5_3141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:26:37Z","timestamp":1769019997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/3141\/8284437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,29]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14494","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"2023-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}